Publication Date:
1979-09-14
Description:
Single-dose administration of pergolide mesylate (100 to 400 micrograms) results in a dose-related inhibition of prolactin secretion which persists for more than 24 hours. During multiple-dose administration of pergolide, plasma prolactin concentrations remain markedly reduced (greater than 80 percnet) and gradually return to control levels several days after drug administration is discontinued.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Lemberger, L -- Crabtree, R E -- New York, N.Y. -- Science. 1979 Sep 14;205(4411):1151-3.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/382359" target="_blank"〉PubMed〈/a〉
Keywords:
Adult
;
Clinical Trials as Topic
;
Dose-Response Relationship, Drug
;
Ergolines/*pharmacology/therapeutic use
;
Humans
;
Informed Consent
;
Male
;
Middle Aged
;
Placebos
;
Prolactin/blood
;
Receptors, Dopamine/*drug effects
;
Time Factors
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
